Joshi Smita, Kulkarni Vinay, Gangakhedkar Raman, Mahajan Uma, Sharma Sushma, Shirole Devendra, Chandhiok Nomita
Department of Preventive Oncology, Hirabai Cowasji Jehangir Medical Research Institute (HCJMRI), Pune, Maharashtra, India.
Prayas Health Group, Amrita Clinic, Pune, Maharashtra, India.
BMJ Open. 2015 Jun 11;5(6):e006718. doi: 10.1136/bmjopen-2014-006718.
To evaluate cost-effectiveness of second HIV test in pregnancy.
Current strategy of single HIV test during pregnancy in India can miss new HIV infections acquired after the first test or those HIV infections that were missed in the first test due to a false-negative HIV test.
Between August 2011 and April 2013, 9097 pregnant HIV uninfected women were offered a second HIV test near term (34 weeks or beyond) or within 4 weeks of postpartum period. A decision analysis model was used to evaluate cost-effectiveness of a second HIV test in pregnant women near term.
Our key outcome measures include programme cost with addition of second HIV test in pregnant women and quality-adjusted life years (QALYs) gained.
We detected 4 new HIV infections in the second test. Thus HIV incidence among pregnant women was 0.12 (95% 0.032 to 0.297) per 100 person women years (PWY). Current strategy of a single HIV test is 8.2 times costlier for less QALYs gained as compared to proposed repeat HIV testing of pregnant women who test negative during the first test.
Our results warrant consideration at the national level for including a second HIV test of all pregnant women in the national programme. However prior to allocation of resources for a second HIV test in pregnancy, appropriate strategies will have to be planned for improving compliance for prevention of mother-to-child transmission of HIV and reducing loss-to-follow-up of those women detected with HIV.
CTRI/2013/12/004183.
评估孕期第二次HIV检测的成本效益。
印度目前孕期单次HIV检测策略可能会遗漏首次检测后新感染的HIV病例,或因首次HIV检测假阴性而漏检的HIV感染病例。
在2011年8月至2013年4月期间,为9097名未感染HIV的孕妇在孕晚期(34周及以后)或产后4周内提供了第二次HIV检测。采用决策分析模型评估孕晚期孕妇第二次HIV检测的成本效益。
我们的关键结果指标包括增加孕妇第二次HIV检测的项目成本以及获得的质量调整生命年(QALY)。
我们在第二次检测中发现了4例新的HIV感染病例。因此,孕妇中HIV发病率为每100人年0.12(95%可信区间为0.032至0.297)。与提议对首次检测呈阴性的孕妇进行重复HIV检测相比,目前单次HIV检测策略成本高8.2倍,而获得的QALY更少。
我们的结果值得在国家层面考虑将所有孕妇的第二次HIV检测纳入国家项目。然而,在为孕期第二次HIV检测分配资源之前,必须制定适当策略,以提高预防HIV母婴传播的依从性,并减少HIV检测呈阳性女性的失访情况。
CTRI/2013/12/004183。